×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 5 Track 2: Advances in CNS Delivery of Oligonucleotides
Session Chair(s)
Jeffrey Foy, PhD
Vice President, Toxicology
PepGen Inc., United States
Lois M. Freed, PhD
Director, Division of Pharmacology/Toxicology-Neuroscience (DPT-N), CDER
FDA, United States
This session will focus on current research efforts in the area of neurological diseases. Improved oligonucleotide delivery and pharmacokinetics/interspecies scaling for neurological assessment based on age and exposure levels will be the focus of the session
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss the new areas of oligonucleotide research and potential treatments for neurological disorders
- Better understand mechanisms of CNS uptake and pharmacokinetics of oligonucleotides
- Identify nonclinical study design considerations for nonclinical studies of oligonucleotides for CNS disorders
Speaker(s)
Expanding the Reach of RNAi Therapeutics
Lan Dang, PhD
Alnylam Pharmaceuticals, United States
Senior Scientist
Comparison of PK Exposure Between Juvenile and Adult Animals After Intrathecal Administration
Daniel Norris, PhD, RPh
Ionis Pharmaceuticals , United States
Executive Director, Pharmacokinetics and Clinical Pharmacology
Overcoming the Blood–Brain Barrier for RNA Therapeutics
Branden Ryu, PhD
BIORCHESTRA Co., Ltd., Korea, Republic of
Cheif Executive Officer
Have an account?